| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Antibody |
| Molecule Category: | UNKNOWN |
| UNII: | 230902QLLC |
Pharmacology
| Primary Target | |
|---|---|
| 4-1BB |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Melanoma | 2 | D008545 | ClinicalTrials |
| Leukemia | 2 | D007938 | ClinicalTrials |
| Neoplasms | 1 | D009369 | ClinicalTrials |
| Neoplasms | 1 | D009369 | ClinicalTrials |
| Multiple Myeloma | 1 | D009101 | ClinicalTrials |
| Lymphoma, Non-Hodgkin | 1 | D008228 | ClinicalTrials |
| Pancreatic Neoplasms | 1 | D010190 | ClinicalTrials |
| Lymphoma, Follicular | 1 | D008224 | ClinicalTrials |
| Gliosarcoma | 1 | D018316 | ClinicalTrials |
| Carcinoma, Non-Small-Cell Lung | 1 | D002289 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 934823-49-1 |
| ChEMBL | CHEMBL1743085 |
| FDA SRS | 230902QLLC |
| Guide to Pharmacology | 9311 |
CONTENTS